Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2024-02-07 Regulatory Filings
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
113年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (旭富) providing information on fund loans and endorsement guarantees for the current and previous month, including limits and cumulative amounts. The content is very short (611 characters) and consists mainly of tabular data without detailed financial statements or analysis. It does not contain comprehensive financial results, management discussion, or regulatory certifications. It appears to be a routine regulatory disclosure of financial guarantees and fund loans, which does not fit into detailed report categories like Annual Report (10-K) or Interim Report (IR). Given the short length and nature of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-02-07 Chinese
113年1月營業收入
Regulatory Filings Classification · 95% confidence The document is a brief financial summary report showing monthly and cumulative net operating revenue figures for a company named 旭富 for the period 民國113年01月 (January 2024). It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document length is only 760 characters, which is very short and contains no detailed financial statements or analysis. It appears to be a regulatory disclosure of monthly revenue figures rather than a full financial report. There is no indication that this is an earnings release or interim report with substantive financial data, nor is it a presentation or announcement of voting results. Given the short length and nature of the content, this fits best as a Regulatory Filing (RNS) which is a general category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-02-07 Chinese
113年01月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and their related parties. It includes data on shares held at appointment, changes during the month, and current holdings, with specific mention of insiders' identities and share types. This type of document is characteristic of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or meeting materials, nor is it a brief announcement or certification. The document length is substantial and contains detailed insider shareholding data, fitting the definition of Director's Dealing (DIRS).
2024-02-05 Chinese
113年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and major shareholders. It lists current holdings, pledged shares, and related party holdings. The content is focused on insider share ownership and changes, which aligns with reporting of personal share transactions or holdings by company directors and executives. The document length is about 3,070 characters, which is relatively short but contains substantive data on insider holdings rather than just an announcement or certification. There is no indication of financial results, audit information, or other report types. Therefore, the document fits best into the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-02-05 Chinese
113年01月法人說明會簡報 — 411920240131E001.pdf
Regulatory Filings
2024-01-31 Chinese
113年01月法人說明會簡報 — 411920240131M001.pdf
Regulatory Filings
2024-01-31 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.